New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
16:07 EDTACHNAchillion granted U.S. patent for ACH-3102, structurally related NS5A inhibitors
Achillion Pharmaceuticals announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus, or HCV, infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
10:15 EDTACHNOptions with decreasing implied volatility
Subscribe for More Information
January 22, 2015
10:35 EDTACHNOptions with decreasing implied volatility
Options with decreasing implied volatility: CZR ACHN NFLX SN NBR TLM CREE BBY LNCO BBRY
January 13, 2015
06:10 EDTACHNAchillion implied volatility of 98 at lower end of index mean range
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use